These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 19642143)
1. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Cui XD; Lee MJ; Yu GR; Kim IH; Yu HC; Song EY; Kim DG Int J Cancer; 2010 Feb; 126(4):940-9. PubMed ID: 19642143 [TBL] [Abstract][Full Text] [Related]
2. Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma. Wada H; Yamamoto H; Kim C; Uemura M; Akita H; Tomimaru Y; Hama N; Kawamoto K; Kobayashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H Int J Oncol; 2014 Sep; 45(3):1051-8. PubMed ID: 24969670 [TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of Ephrin-A1 in primary hepatocellular carcinoma]. Zhang G; Zhang SJ; Zhao YF; Wu Y; Li Z; Wang JX Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):499-502. PubMed ID: 17686315 [TBL] [Abstract][Full Text] [Related]
4. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Iida H; Honda M; Kawai HF; Yamashita T; Shirota Y; Wang BC; Miao H; Kaneko S Gut; 2005 Jun; 54(6):843-51. PubMed ID: 15888795 [TBL] [Abstract][Full Text] [Related]
5. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472 [TBL] [Abstract][Full Text] [Related]
6. EPHA2/EFNA1 expression in human gastric cancer. Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254 [TBL] [Abstract][Full Text] [Related]
7. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Ma H; Liang X; Chen Y; Pan K; Sun J; Wang H; Wang Q; Li Y; Zhao J; Li J; Chen M; Xia J Int J Cancer; 2011 Feb; 128(4):771-7. PubMed ID: 20473897 [TBL] [Abstract][Full Text] [Related]
8. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865 [TBL] [Abstract][Full Text] [Related]
9. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Ikeguchi M; Ueta T; Yamane Y; Hirooka Y; Kaibara N Clin Cancer Res; 2002 Oct; 8(10):3131-6. PubMed ID: 12374680 [TBL] [Abstract][Full Text] [Related]
10. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847 [TBL] [Abstract][Full Text] [Related]
11. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma. Guo X; Yang M; Gu H; Zhao J; Zou L Cancer Epidemiol; 2013 Oct; 37(5):732-6. PubMed ID: 23731550 [TBL] [Abstract][Full Text] [Related]
12. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804 [TBL] [Abstract][Full Text] [Related]
13. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Zhou ZJ; Dai Z; Zhou SL; Fu XT; Zhao YM; Shi YH; Zhou J; Fan J Int J Cancer; 2013 Mar; 132(5):1080-9. PubMed ID: 22821376 [TBL] [Abstract][Full Text] [Related]
15. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374 [TBL] [Abstract][Full Text] [Related]
16. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma. Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282 [TBL] [Abstract][Full Text] [Related]
17. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337 [TBL] [Abstract][Full Text] [Related]
19. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285 [TBL] [Abstract][Full Text] [Related]
20. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]